The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

While inbred mice have informed most of what we know about the immune system in the
modern era, they have clear limitations with respect to their ability to be informative …

Even given recent advances in nanomedicine development of breast cancer treatment in
recent years and promising results in pre-clinical models, cancer nanomedicines often fail at …

Background Tumor cell-intrinsic mechanisms and complex interactions with the tumor
microenvironment contribute to therapeutic failure via tumor evolution. It may be possible to …

Colorectal cancer (CRC) is the third most common diagnosed malignancy among both
sexes in the United States as well as in the European Union. While the incidence and …

Malignant brain tumors remain uniformly fatal, even with the best-to-date treatment. For
Glioblastoma (GBM), the most severe form of brain cancer in adults, the median overall …

Lentinan (SLNT) has been shown to be directly cytotoxic to cancer cells. However, this direct
antitumour effect has not been thoroughly investigated in vivo, and the mechanism remains …

Due to the limitations of autologous chimeric antigen receptor (CAR)-T cells, alternative
sources of cellular immunotherapy, including CAR macrophages, are emerging for solid …

Investigation of the efficacy and mechanisms of human immuno-oncology agents has been
hampered due to species-specific differences when utilizing preclinical mouse models …

ABSTRACT A major impediment to successful use of therapeutic protein drugs is their ability
to induce anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a …